News & Events
Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
SAN DIEGO – October 26, 2017 – Crinetics Pharmaceuticals, Inc. , a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the initiation of a Phase 1, double-blind, randomized, placebo-controlled, single- and-multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CRN00808 in healthy volunteers. CRN00808 is a nonpeptide somatostatin agonist designed to be taken orally to free patients from painful injected therapies and the scheduling of frequent clinic visits to receive them.
READ MORECrinetics Pharmaceuticals Awarded Two SBIR Grants to Develop New Therapeutics for Congenital Hyperinsulinism and Cushing’s Disease
SAN DIEGO – September 6, 2017 – Crinetics Pharmaceuticals, Inc. , a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that it was awarded two new grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) that could total $2. 4 million.
READ MORECrinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
SAN DIEGO – July 13, 2017 – Crinetics Pharmaceuticals, Inc. , a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that it was awarded a Phase IIB Small Business Innovation Research (SBIR) grant of up to $2. 8 million from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).
READ MORECrinetics Pharmaceuticals Appoints Anne Klibanski, M.D. to Scientific Advisory Board
SAN DIEGO – November 10, 2016 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on specialty endocrine disorders and endocrine-related cancers, announced today the addition of Anne Klibanski, M. D. as a member of the company’s scientific advisory board.
READ MORECrinetics Pharmaceuticals Appoints Ajay Madan as Vice President, Development
SAN DIEGO – June 6, 2016 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on specialty endocrine disorders, announced today the addition of Ajay Madan, Ph. D. , D.
READ MOREThe San Diego Union-Tribune: Crinetics raises $40 Million
November 2, 2015 — Seeking to get its first drug ready for human testing, San Diego biotech Crinetics Pharmaceuticals has raised $40 million in venture capital funding.
READ MOREXconomy: Crinetics Pharma Raises $40M in Comeback for Ex-Neurocrine Bio Team
November 2, 2015 — After spending the past six years scavenging for lab equipment and operating on a shoestring, San Diego’s Crinetics Pharmaceuticals has finally landed its first round of institutional funding.
READ MORECrinetics Pharmaceuticals Completes $40 Million Series A Financing
SAN DIEGO – November 2, 2015 – Crinetics Pharmaceuticals, an innovative therapeutics company focused on specialty endocrine disorders, announced today the completion of a $40 million series A financing led by 5AM Ventures, Versant Ventures, and Vivo Capital. Crinetics plans to use the proceeds to advance development of its small molecule somatostatin agonist program to clinical proof-of-concept for the treatment of acromegaly, as well as to move additional programs into development.
READ MORECrinetics Pharmaceuticals Appoints Matt Fust, M.B.A., David Clemons, M.D., and John Wallen, Ph.D., J.D. as Corporate, Clinical, and Legal Advisers
SAN DIEGO – April 27, 2015 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on endocrine diseases and cancers, announced today the addition of corporate, clinical, and legal advisers as the company prepares for the clinical development of its pipeline of first- and best-in-class medicines.
READ MORECrinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain
SAN DIEGO – April 27, 2015 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on endocrine diseases and cancers, announced today that it has been awarded Phase I of a Fast-Track Small Business Innovation Research (SBIR) grant of up to $2. 7MM from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) for the development of orally-available, small molecule somatostatin receptor agonist drugs for the treatment of chronic and neuropathic pain disorders.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
